StarZero All shows Try the podcast clipper →

Feb 24, 2018 · 18m · top-founders

945 He's Democratizing Health Data Across Big Pharma With 200 Customers, $3.5m Revenue

Gunjan Bhardwaj · 9m spoken Nathan Latka · 7m spoken
0:00 / 0:00

gold bands on the timeline = statements, start to end. Hover to read, click to jump. CC turns on captions

In this episode of The Top Entrepreneurs, host Nathan Latka interviews InnoPlexus founder Gunjan Bhardwaj to explore how the AI-driven life sciences platform bootstrapped, scaled to €3.5 million in annual recurring revenue across major pharmaceutical enterprises, and maintains zero customer churn.

How this conversation actually went

Every chapter scored 0–10 on four independent dynamics. Hover any point for the reasoning behind the score. Nathan holds 44.7% of the talking time here. How this is scored →

Nathan as informed peer 5.2 Guest teaching 3.0 Guest disagreement 2.0 Nathan pushing back 4.0
05100:0010:000:49–4:27 · Nathan as informed peer 5/10 Introducing Gunjan Bhardwaj and InnoPlexus Latka repeatedly presses Bhardwaj to move past high-level buzzwords and clarify the exact business model and pricing per seat.4:27–7:02 · Nathan as informed peer 4/10 Bootstrapping Origins, Venture Capital, and Team Expansion Bhardwaj explains the origin story, technical focus on data inputs versus algorithms, and transition from bootstrapping to raising venture capital.7:02–9:13 · Nathan as informed peer 4/10 Enterprise Pharma Sales Strategy and Proof of Concept Scaling The conversation covers enterprise sales strategy within pharma, detailing how initial proof-of-concept projects scale into wider enterprise licenses.9:15–13:53 · Nathan as informed peer 7/10 Sponsor Segment: Acquiring and Scaling The Top Inbox Following a sponsor read, Latka estimates revenue numbers and challenges Bhardwaj's zero-churn metric by arguing he should triple prices, which Bhardwaj defends on mission grounds.13:54–17:00 · Nathan as informed peer 7/10 Unit Economics, Customer Lifetime Value, and Patent Strategy Latka drills down on CAC and LTV assumptions, questioning vague corporate jargon about commercial presence and calculating implied acquisition spend.17:00–18:49 · Nathan as informed peer 4/10 The Famous Five Rapid-Fire Questions Latka runs through the rapid-fire questions cleanly and wraps up with a thorough executive summary of InnoPlexus's core metrics.0:49–4:27 · Guest teaching 4/10 Introducing Gunjan Bhardwaj and InnoPlexus Latka repeatedly presses Bhardwaj to move past high-level buzzwords and clarify the exact business model and pricing per seat.4:27–7:02 · Guest teaching 3/10 Bootstrapping Origins, Venture Capital, and Team Expansion Bhardwaj explains the origin story, technical focus on data inputs versus algorithms, and transition from bootstrapping to raising venture capital.7:02–9:13 · Guest teaching 3/10 Enterprise Pharma Sales Strategy and Proof of Concept Scaling The conversation covers enterprise sales strategy within pharma, detailing how initial proof-of-concept projects scale into wider enterprise licenses.9:15–13:53 · Guest teaching 3/10 Sponsor Segment: Acquiring and Scaling The Top Inbox Following a sponsor read, Latka estimates revenue numbers and challenges Bhardwaj's zero-churn metric by arguing he should triple prices, which Bhardwaj defends on mission grounds.13:54–17:00 · Guest teaching 4/10 Unit Economics, Customer Lifetime Value, and Patent Strategy Latka drills down on CAC and LTV assumptions, questioning vague corporate jargon about commercial presence and calculating implied acquisition spend.17:00–18:49 · Guest teaching 1/10 The Famous Five Rapid-Fire Questions Latka runs through the rapid-fire questions cleanly and wraps up with a thorough executive summary of InnoPlexus's core metrics.0:49–4:27 · Guest disagreement 2/10 Introducing Gunjan Bhardwaj and InnoPlexus Latka repeatedly presses Bhardwaj to move past high-level buzzwords and clarify the exact business model and pricing per seat.4:27–7:02 · Guest disagreement 1/10 Bootstrapping Origins, Venture Capital, and Team Expansion Bhardwaj explains the origin story, technical focus on data inputs versus algorithms, and transition from bootstrapping to raising venture capital.7:02–9:13 · Guest disagreement 1/10 Enterprise Pharma Sales Strategy and Proof of Concept Scaling The conversation covers enterprise sales strategy within pharma, detailing how initial proof-of-concept projects scale into wider enterprise licenses.9:15–13:53 · Guest disagreement 4/10 Sponsor Segment: Acquiring and Scaling The Top Inbox Following a sponsor read, Latka estimates revenue numbers and challenges Bhardwaj's zero-churn metric by arguing he should triple prices, which Bhardwaj defends on mission grounds.13:54–17:00 · Guest disagreement 3/10 Unit Economics, Customer Lifetime Value, and Patent Strategy Latka drills down on CAC and LTV assumptions, questioning vague corporate jargon about commercial presence and calculating implied acquisition spend.17:00–18:49 · Guest disagreement 1/10 The Famous Five Rapid-Fire Questions Latka runs through the rapid-fire questions cleanly and wraps up with a thorough executive summary of InnoPlexus's core metrics.0:49–4:27 · Nathan pushing back 5/10 Introducing Gunjan Bhardwaj and InnoPlexus Latka repeatedly presses Bhardwaj to move past high-level buzzwords and clarify the exact business model and pricing per seat.4:27–7:02 · Nathan pushing back 2/10 Bootstrapping Origins, Venture Capital, and Team Expansion Bhardwaj explains the origin story, technical focus on data inputs versus algorithms, and transition from bootstrapping to raising venture capital.7:02–9:13 · Nathan pushing back 2/10 Enterprise Pharma Sales Strategy and Proof of Concept Scaling The conversation covers enterprise sales strategy within pharma, detailing how initial proof-of-concept projects scale into wider enterprise licenses.9:15–13:53 · Nathan pushing back 7/10 Sponsor Segment: Acquiring and Scaling The Top Inbox Following a sponsor read, Latka estimates revenue numbers and challenges Bhardwaj's zero-churn metric by arguing he should triple prices, which Bhardwaj defends on mission grounds.13:54–17:00 · Nathan pushing back 7/10 Unit Economics, Customer Lifetime Value, and Patent Strategy Latka drills down on CAC and LTV assumptions, questioning vague corporate jargon about commercial presence and calculating implied acquisition spend.17:00–18:49 · Nathan pushing back 1/10 The Famous Five Rapid-Fire Questions Latka runs through the rapid-fire questions cleanly and wraps up with a thorough executive summary of InnoPlexus's core metrics.

speaking balance: gold is Nathan, purple is the guest (3 minute bins)

0:00 · Nathan 51.6% · guest 48.4%0:00 · Nathan 51.6% · guest 48.4%3:00 · Nathan 18.7% · guest 81.3%3:00 · Nathan 18.7% · guest 81.3%6:00 · Nathan 35.8% · guest 64.2%6:00 · Nathan 35.8% · guest 64.2%9:00 · Nathan 65.5% · guest 34.5%9:00 · Nathan 65.5% · guest 34.5%12:00 · Nathan 39.4% · guest 60.6%12:00 · Nathan 39.4% · guest 60.6%15:00 · Nathan 41.4% · guest 58.6%15:00 · Nathan 41.4% · guest 58.6%18:00 · Nathan 94.3% · guest 5.7%18:00 · Nathan 94.3% · guest 5.7%
Sharpest disagreement ▶ 13:13 Guest rejects pure profit maximization premise

Bhardwaj resists Latka's insistence on tripling prices, arguing that the life sciences sector requires balancing monetization with patient health outcomes.

 Hardest push from Nathan ▶ 13:28 Host calls out guest's altruistic framing

Latka pushes back against Bhardwaj's mission-driven framing, directly calling him a fellow capitalist who aims to maximize revenue.

 Biggest teaching moment ▶ 2:54 Guest outlines AI disruption of legacy data curating

Bhardwaj educates Latka on how AI models are replacing traditional monopolies that rely on thousands of manual data analysts in India and China.

 Nathan holds their own ▶ 15:52 Host deduces CAC from customer lifetime value

Latka runs through quick arithmetic on seat price, multi-year lifetime value, and target LTV-to-CAC ratios to pin down the company's real acquisition cost ceiling.
the scores for every segment, with the reasoning behind each
ChapterTopicNathan as informed peerGuest teachingGuest disagreementNathan pushing backWhy
Introducing Gunjan Bhardwaj and InnoPlexus 5425 Latka repeatedly presses Bhardwaj to move past high-level buzzwords and clarify the exact business model and pricing per seat.
Bootstrapping Origins, Venture Capital, and Team Expansion 4312 Bhardwaj explains the origin story, technical focus on data inputs versus algorithms, and transition from bootstrapping to raising venture capital.
Enterprise Pharma Sales Strategy and Proof of Concept Scaling 4312 The conversation covers enterprise sales strategy within pharma, detailing how initial proof-of-concept projects scale into wider enterprise licenses.
Sponsor Segment: Acquiring and Scaling The Top Inbox 7347 Following a sponsor read, Latka estimates revenue numbers and challenges Bhardwaj's zero-churn metric by arguing he should triple prices, which Bhardwaj defends on mission grounds.
Unit Economics, Customer Lifetime Value, and Patent Strategy 7437 Latka drills down on CAC and LTV assumptions, questioning vague corporate jargon about commercial presence and calculating implied acquisition spend.
The Famous Five Rapid-Fire Questions 4111 Latka runs through the rapid-fire questions cleanly and wraps up with a thorough executive summary of InnoPlexus's core metrics.

Statements from this episode (10)

Assertion Not checkable as stated
InnoPlexus replaces Indian and Chinese manual data curation monopolies with AI
“That has been a monopoly of large data service companies manually curating data, hiring thousands of analysts in India and China. We are replacing all of that using AI leveraged algorithms.”
Gunjan Bhardwaj Feb 24, 2018 ▶ 3:00
Disclosure
InnoPlexus charges six figures annually for a ten-user SaaS deployment
“Well, as I mentioned it depends on the number of users for something like 10 users or so, it could the price could go range of six digit dollar figures. Depending on what indication and what therapeutic area they are looking at.”
Gunjan Bhardwaj Feb 24, 2018 ▶ 3:56
Assertion Not publicly verifiable
InnoPlexus raises around $10M in total venture capital
“It was till now including pre-series A, we have raised around ten million dollars.”
Gunjan Bhardwaj Feb 24, 2018 ▶ 5:55
Assertion Not checkable as stated
InnoPlexus generates 85% of revenue from recurring SaaS
“85%.”
Gunjan Bhardwaj Feb 24, 2018 ▶ 6:36
Assertion Not checkable as stated
InnoPlexus reaches team size of around 140 people
“We are around 140 people.”
Gunjan Bhardwaj Feb 24, 2018 ▶ 6:42
Disclosure
Bhardwaj: InnoPlexus serves around six major pharmaceutical clients
“So we have around six big pharma clients for various therapeutic areas.”
Gunjan Bhardwaj Feb 24, 2018 ▶ 7:08
Assertion Not checkable as stated
InnoPlexus operates at a revenue run rate slightly over €3.5M
“In terms of run rate, we would be slightly above half of that.”
Gunjan Bhardwaj Feb 24, 2018 ▶ 11:48
Prediction Not publicly verifiable
Bhardwaj projects InnoPlexus will reach approximately €8M in revenue next year
“We'll do around eight.”
Gunjan Bhardwaj Feb 24, 2018 ▶ 12:05
Assertion Not checkable as stated
InnoPlexus reports zero customer churn for its licensed software products
“We haven't lost a single client that has licensed our products.”
Gunjan Bhardwaj Feb 24, 2018 ▶ 12:59
Assertion Supported
Bhardwaj: InnoPlexus holds 15 patent applications with substantial growth expected
“We have 15 patent applications as we speak, and that number is going to increase next year substantially.”
Gunjan Bhardwaj Feb 24, 2018 ▶ 15:42
Made with StarZero

Turn any episode into a week of clips.

This entire site, over 2,600 episodes transcribed, diarized, checked and made playable, runs on the StarZero media pipeline. Drop in your own episode and the podcast clipper finds the moments worth sharing, cuts them, captions them, and reframes them for every feed.

Try the podcast clipper Learn more